Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

MNPR

Monopar Therapeutics Inc

May 16 • 04:00PM ET

0.6175

Dollar change +0.0194
Percentage change 3.24	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	48.82%	Shs Outstand	14.90M	Perf Week	-13.16%
Market Cap	10.79M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	0.00%	Shs Float	8.95M	Perf Month	-5.73%
Income	-7.61M	PEG	-	EPS next Q	-0.09	Inst Own	2.28%	Short Float	1.03%	Perf Quarter	81.56%
Sales	0.00M	P/S	-	EPS this Y	37.70%	Inst Trans	-2.78%	Short Ratio	0.02	Perf Half Y	88.26%
Book/sh	0.43	P/B	1.44	EPS next Y	17.11%	ROA	-73.36%	Short Interest	0.09M	Perf Year	-27.51%
Cash/sh	0.50	P/C	1.23	EPS next 5Y	-	ROE	-92.67%	52W Range	0.27 - 1.75	Perf YTD	81.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-14.79%	ROI	-101.76%	52W High	-64.71%	Beta	1.14
Dividend TTM	-	Quick Ratio	6.21	Sales past 5Y	0.00%	Gross Margin	-	52W Low	125.45%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	6.21	EPS Y/Y TTM	35.48%	Oper. Margin	0.00%	RSI (14)	42.41	Volatility	11.72% 9.28%
Employees	10	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.33
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	44.73%	Payout	-	Rel Volume	0.01	Prev Close	0.60
Sales Surprise	-	EPS Surprise	31.03%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	5.51M	Price	0.62
SMA20	-8.53%	SMA50	-12.32%	SMA200	10.14%	Trades		Volume	34,440	Change	3.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-21	Initiated	ROTH Capital	Buy	$49

May-09-24 01:55PM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19%
07:00AM	Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline (GlobeNewswire)
Apr-18-24 08:00AM	Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 08:00AM	Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings (GlobeNewswire)
Apr-10-24 08:00AM	Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients (GlobeNewswire) +8.36%
09:55AM	Loading…
Apr-04-24 09:55AM	Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-03-24 12:00PM	All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy (Zacks)
Mar-28-24 11:53AM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.60%
07:00AM	Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments (GlobeNewswire)
Mar-05-24 07:00AM	Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program (GlobeNewswire) +7.06%
Feb-27-24 07:00AM	Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial (GlobeNewswire) -10.37%
Feb-23-24 11:55AM	5 Best Rising Penny Stocks To Buy (Insider Monkey) +16.07%
Feb-22-24 07:00AM	Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers (GlobeNewswire) +96.49%
Feb-20-24 08:00AM	Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers (GlobeNewswire) +95.27%
Nov-09-23 08:37AM	Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs (GuruFocus.com)
07:00AM	Loading…
07:00AM	Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Nov-01-23 07:00AM	Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire) +27.91%
Oct-10-23 07:00AM	Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -5.96%
Sep-05-23 07:00AM	Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 07:00AM	Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Aug-08-23 07:00AM	Monopar Provides Encouraging Camsirubicin Clinical Data Update (GlobeNewswire) +15.22%
Jul-11-23 07:00AM	Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore (GlobeNewswire)
Jun-21-23 07:00AM	Monopar to Participate in the Radiopharma Forum by the Lake 2023 (GlobeNewswire)
Jun-14-23 07:00AM	Monopar to Participate in the Maxim Groups Healthcare Virtual Conference (GlobeNewswire)
Jun-01-23 07:00AM	Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update (GlobeNewswire) +7.36%
May-29-23 09:55AM	Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-11-23 07:00AM	Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments (GlobeNewswire) -6.58%
Apr-19-23 09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-28-23 01:40PM	Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication (Benzinga) -51.34%
07:00AM	Monopar to Present at the Jefferies Radiopharma Innovation Summit (GlobeNewswire)
05:00PM	Loading…
Mar-27-23 05:00PM	Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis (GlobeNewswire)
Mar-23-23 07:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments (GlobeNewswire)
Mar-07-23 07:00AM	Monopar to Present at the 35th Annual Roth Conference (GlobeNewswire)
Feb-27-23 07:00AM	Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials (GlobeNewswire)
Feb-14-23 12:46PM	What's Going On With Monopar Therapeutics Shares Today? (Benzinga)
07:00AM	Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin (GlobeNewswire)
Feb-05-23 08:38AM	We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate (Simply Wall St.)
Jan-26-23 07:00AM	Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT (GlobeNewswire)
Jan-18-23 07:00AM	Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 (GlobeNewswire)
Dec-12-22 07:00AM	Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration (GlobeNewswire) -18.97%
Nov-18-22 01:10PM	Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data (Zacks) -6.42%
09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-16-22 10:09AM	Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Study (Benzinga)
07:00AM	Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial (GlobeNewswire)
Nov-10-22 08:00AM	Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) -24.83%
Oct-27-22 08:00AM	Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 (GlobeNewswire)
Oct-19-22 08:00AM	Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting (GlobeNewswire)
Oct-12-22 08:00AM	Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire)
Oct-05-22 08:50AM	Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients (MarketWatch)
08:00AM	Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis (GlobeNewswire)
Sep-28-22 08:00AM	Monopar to Present at Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire)
Aug-28-22 10:49AM	Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation (Simply Wall St.)
Aug-18-22 09:55AM	Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-11-22 08:05AM	Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire)
May-12-22 08:00AM	Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) -7.96%
Mar-24-22 08:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments (GlobeNewswire)
Mar-21-22 03:18PM	Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-08-22 08:00AM	Monopar to Present at the 34th Annual Roth Conference and Maxims 2022 Virtual Growth Conference (GlobeNewswire) -5.98%
Feb-15-22 08:05AM	Monopar Announces Clinical and Preclinical Program Updates (GlobeNewswire) +6.16%
Jan-07-22 07:05AM	Monopar to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire) +6.67%
Dec-08-21 08:00AM	Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial (GlobeNewswire)
Nov-12-21 08:00AM	Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments (GlobeNewswire)
Oct-27-21 08:05AM	Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma (GlobeNewswire) +8.34%
Sep-22-21 08:30AM	Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-16-21 08:00AM	Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma (GlobeNewswire)
Sep-13-21 08:00AM	Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe (GlobeNewswire) -7.55%
Sep-09-21 08:00AM	Monopar Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) +9.89%
Aug-12-21 08:00AM	Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates (GlobeNewswire)
Aug-05-21 08:00AM	Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial (GlobeNewswire)
Aug-03-21 08:00AM	Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma (GlobeNewswire)
Jul-12-21 08:00AM	Monopar Appoints Octávio Costa, MD, as Chief Medical Officer (GlobeNewswire)
Jun-24-21 08:00AM	Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO (GlobeNewswire) +7.99%
Jun-03-21 08:00AM	Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer (GlobeNewswire)
May-26-21 08:00AM	Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic (GlobeNewswire) +9.71%
May-24-21 08:00AM	Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery (GlobeNewswire)
May-13-21 04:42PM	Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates (GlobeNewswire)
Mar-30-21 10:13AM	Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer (Benzinga) +16.32%
07:30AM	Monopars uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study (GlobeNewswire)
Mar-26-21 06:22AM	Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-25-21 08:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates (GlobeNewswire) -6.40%
Mar-02-21 07:30AM	Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery (GlobeNewswire)
Feb-24-21 07:30AM	Monopar Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +5.31%
Feb-18-21 07:00AM	Monopar Expands Clinical Team with Appointment of Laura Kelly as Director of Clinical Operations (GlobeNewswire) -9.39%
Feb-16-21 07:30AM	Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC) (GlobeNewswire) -5.01%
Feb-11-21 07:30AM	Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer (GlobeNewswire) +26.19%
Feb-09-21 07:00AM	Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada (GlobeNewswire)
Dec-28-20 08:33AM	Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4% (Zacks) -14.55%
Dec-22-20 08:30AM	Monopar Announces Issuance of U.S. Patent Covering Compositions of Matter for a Novel Family of Camsirubicin Analogs (GlobeNewswire) +6.56%
Dec-10-20 08:30AM	Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19 (GlobeNewswire) +8.13%
Dec-08-20 08:30AM	Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC) (GlobeNewswire) +7.43%
Nov-12-20 09:15AM	Monopar Therapeutics Reports Third Quarter 2020 Financial Results and Business Update (GlobeNewswire)
Nov-09-20 08:30AM	Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive® (GlobeNewswire)
Sep-14-20 08:30AM	Monopar Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 (GlobeNewswire)
Sep-09-20 08:30AM	Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19 (GlobeNewswire)
Aug-19-20 08:30AM	Monopar and NorthStar Partner with Aragen for Testing of Novel Potential Therapeutic for Severe COVID-19 (GlobeNewswire) +10.57%
Aug-12-20 08:30AM	Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology (GlobeNewswire) -5.45%
Aug-10-20 08:30AM	Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19 (GlobeNewswire) +9.57%
Aug-06-20 04:05PM	Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates (GlobeNewswire)
Jun-30-20 08:25AM	Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR (GlobeNewswire) +8.12%
Jun-17-20 07:53AM	We're Excited To See How Monopar Therapeutics (NASDAQ:MNPR) Uses Its Cash Hoard To Grow (Simply Wall St.) -10.84%

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNPR

Monopar Therapeutics Inc

Upgrade your FINVIZ experience